Loading stock data…
MASI
$179.95+0.01 (+0.01%)
After Hours$179.95+0.00 (+0.00%)· Last close Jun 9
Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Masimo Corporation in the Healthcare sector is trading at $179.95 with a market capitalization of $9.4B. Wall Street consensus targets $180.00 (4 analysts), implying a +0.0% move over the next 12 months. The stock is currently near its 52-week high of $179.99, remaining 15.4% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$179.95
Potential Upside
52.2%
Whystock Fair Value$273.86
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Mean target$180.00+0.0%
Range$180.00 – $180.00
Fundamentals
Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide. It offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.36B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
44.25
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.13
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
9.67%
Volume
Today's trading volume
3.09M
Recent News
Wolfe Research Downgrades Danaher Corporation (DHR)
Danaher Corporation (NYSE:DHR) is one of the best healthcare stocks to buy with highest upside potential. Wolfe Research downgraded Danaher Corporation (NYSE:DHR) to Peer Perform from Outperform on June 1 without assigning a price target after assuming coverage of the name. It stated that growth forward and backward is similar, and Thermo Fisher is “a […]
SIRI Stock Surges 5% After-Hours On S&P MidCap 400 Inclusion
The index provider said Sirius XM will take Masimo’s (MASI) slot in the benchmark effective prior to the market open on Thursday, June 11.
Is It Too Late To Consider Masimo (MASI) After A 40% Year To Date Rally?
Investors may be considering whether Masimo at around US$178.82 is offering good value right now, or if the recent run leaves limited room for further upside. The stock has been relatively flat over the past week and month at 0.2%. It is up 40.4% year to date and 4.0% over the past year, which can change how investors think about both opportunity and risk. Recent coverage has focused on Masimo as a medical technology company in the healthcare sector, which keeps it on the radar of investors...
IART vs. MASI: Which Stock Should Value Investors Buy Now?
IART vs. MASI: Which Stock Is the Better Value Option?
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
MediWound (MDWD) delivered earnings and revenue surprises of +64.79% and -56.10%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?